Trial · NCT00274781
Adverse events33
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 33
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Vascular disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 16 | 30 | |
| other | Neutropenia | Blood and lymphatic system disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 20 | 30 | |
| other | Anemia | Blood and lymphatic system disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 22 | 30 | |
| other | Fatigue | Musculoskeletal and connective tissue disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 28 | 30 | |
| other | Rash / Pruritis | Skin and subcutaneous tissue disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 12 | 30 | |
| other | Pain | Musculoskeletal and connective tissue disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 16 | 30 | |
| other | Edema | Blood and lymphatic system disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 9 | 30 | |
| other | Nausea / Vomiting / Dyspepsia | Gastrointestinal disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 18 | 30 | |
| other | Diarrhea / Constipation | Gastrointestinal disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 20 | 30 | |
| other | Dyspnea | Respiratory, thoracic and mediastinal disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 15 | 30 | |
| other | Anorexia / Decreased Appetite | Metabolism and nutrition disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 10 | 30 | |
| other | Pyrexia | Immune system disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 15 | 30 | |
| other | Cough | Respiratory, thoracic and mediastinal disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 11 | 30 | |
| other | Insomnia | General disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 4 | 30 | |
| other | Catheter / Infusion Site Disorders / Infections | Infections and infestations | ATO (0.25mg/kg) and GO (3mg/m2) | 4 | 30 | |
| other | Abdominal Pain | Musculoskeletal and connective tissue disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 6 | 30 | |
| other | Cardiac Arrhythmia | Cardiac disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 8 | 30 | |
| other | Pneumonia | Infections and infestations | ATO (0.25mg/kg) and GO (3mg/m2) | 8 | 30 | |
| other | Headache | Nervous system disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 11 | 30 | |
| other | QT / QTc Interval Prolongation | Cardiac disorders | ATO (0.25mg/kg) and GO (3mg/m2) | 4 | 30 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00274781/events